Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060138 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00060138: Completed Phase 1 study, sponsored by Chugai Pharmaceutical.
NCT00060138 is a Phase 1 study that has completed, run by Chugai Pharmaceutical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00060138, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal antibody is more effective than zoledronate in treating women who have breast cancer and bone metastases. PURPOSE: Randomized phase I/II trial to compare the effectiveness of monoclonal antibody with that of zoledronate in treating women who have breast cancer and bone metastases.
Interventions
- DRUG zoledronic acid
- BIOLOGICAL monoclonal antibody CAL
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-11 |
| Phase | Phase 1 |
What the finished NCT00060138 record still lists
NCT00060138 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which zoledronic acid is the first listed.
NCT00060138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00060138 about?
NCT00060138 is a clinical study titled "Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. It is not yet known whether monoclonal antibody is more effective than ...
What is the current status of trial NCT00060138?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-11.
What interventions are being tested in trial NCT00060138?
The interventions under investigation include: zoledronic acid (DRUG), monoclonal antibody CAL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00060138?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia